Drug Profile
AVA 004
Alternative Names: AVA-004; AVA004-251Fc; AVA04Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Avacta
- Class Antineoplastics; Proteins
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 10 Jun 2019 Avacta plans a phase I trial for Solid tumours (Late-stage disease) in North America and Europe
- 10 Jun 2019 Avacta announces intention to submit an IND and a CTA application for Solid tumours, by the end of 2020